-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70

Benzinga·11/09/2026 15:20:06
Diffusion vocale
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $110 to $70.